These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20086170)

  • 1. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.
    Jia Z; Gao Y; Wang L; Li Q; Zhang J; Le X; Wei D; Yao JC; Chang DZ; Huang S; Xie K
    Cancer Res; 2010 Feb; 70(3):1111-9. PubMed ID: 20086170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.
    Gao Y; Jia Z; Kong X; Li Q; Chang DZ; Wei D; Le X; Suyun H; Huang S; Wang L; Xie K
    Cancer Res; 2011 Aug; 71(15):5182-93. PubMed ID: 21673052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment of pancreatic cancer with mithramycin a and tolfenamic Acid promotes sp1 degradation and synergistic antitumor activity--letter.
    Chou TC
    Cancer Res; 2011 Apr; 71(7):2793; discussion 2794-800. PubMed ID: 21447740
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
    Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
    Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
    Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
    J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
    Yuan P; Wang L; Wei D; Zhang J; Jia Z; Li Q; Le X; Wang H; Yao J; Xie K
    Cancer; 2007 Dec; 110(12):2682-90. PubMed ID: 17973266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
    Wei D; Wang L; He Y; Xiong HQ; Abbruzzese JL; Xie K
    Cancer Res; 2004 Mar; 64(6):2030-8. PubMed ID: 15026340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.
    Hurtado M; Sankpal UT; Kaba A; Mahammad S; Chhabra J; Brown DT; Gurung RK; Holder AA; Vishwanatha JK; Basha R
    Cell Physiol Biochem; 2018; 51(4):1894-1907. PubMed ID: 30504717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth.
    Shelake S; Sankpal UT; Paul Bowman W; Wise M; Ray A; Basha R
    Invest New Drugs; 2017 Apr; 35(2):158-165. PubMed ID: 28025760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.
    Liu XJ; Li L; Liu XJ; Li Y; Zhao CY; Wang RQ; Zhen YS
    Int J Nanomedicine; 2017; 12():5255-5269. PubMed ID: 28769562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.
    Eslin D; Lee C; Sankpal UT; Maliakal P; Sutphin RM; Abraham L; Basha R
    Tumour Biol; 2013 Oct; 34(5):2781-9. PubMed ID: 23686785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.
    Previdi S; Malek A; Albertini V; Riva C; Capella C; Broggini M; Carbone GM; Rohr J; Catapano CV
    Gynecol Oncol; 2010 Aug; 118(2):182-8. PubMed ID: 20452660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor Sp1 is upregulated by PKCĪ¹ to drive the expression of YAP1 during pancreatic carcinogenesis.
    Yang J; Wang J; Zhang H; Li C; Chen C; Zhu T
    Carcinogenesis; 2021 Apr; 42(3):344-356. PubMed ID: 33146712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
    Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
    Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models.
    Wang L; Guan X; Zhang J; Jia Z; Wei D; Li Q; Yao J; Xie K
    Int J Oncol; 2008 Jul; 33(1):161-7. PubMed ID: 18575762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.
    Jutooru I; Chadalapaka G; Lei P; Safe S
    J Biol Chem; 2010 Aug; 285(33):25332-44. PubMed ID: 20538607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1.
    Shim JH; Shin JA; Jung JY; Choi KH; Choi ES; Cho NP; Kong G; Ryu MH; Chae JI; Cho SD
    Eur J Cancer Prev; 2011 Mar; 20(2):102-11. PubMed ID: 21131823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth.
    Hsu TI; Wang MC; Chen SY; Huang ST; Yeh YM; Su WC; Chang WC; Hung JJ
    Mol Pharmacol; 2012 Dec; 82(6):1115-28. PubMed ID: 22956772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells.
    Sankpal UT; Goodison S; Jones-Pauley M; Hurtado M; Zhang F; Basha R
    Oncotarget; 2017 Feb; 8(9):14593-14603. PubMed ID: 28099934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
    Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
    Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.